Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
None (14) ·
(multiple, generic dominant) (1) ·
Dalmane (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Doral (1) ·
Duragesic (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Nubain (1) ·
Nucynta (1) ·
Onfi (1) ·
Opana (1) ·
ProSom (1) ·
Restoril (1) ·
Rexulti (1) ·
Rohypnol (1) ·
Serax (1) ·
Stadol (1) ·
Suboxone (1) ·
Talwin (1) ·
Tranxene (1) ·
Versed (1) ·
Vicodin (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)
uses:
None (39) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
preparations:
None (39) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 42 results in range #1 to #42.